Safety and immunogenicity of dTpa vaccine administered in pregnancy

Project Details

A phase IV, observer-blind, placebo-controlled and randomised study will be conducted to assess the safety and immunogenicity of dTpa vaccine given during 27-36 weeks of gestation in healthy women aged 18-45 years. We aim to demonstrate that the immunogenicity of a single dose of dTpa vaccine is superior to controls in terms of pertussis antibodies, in the cord blood sample. Safety wil also be evaluated.

Researchers

Professor Terry Nolan

Dr Kirsten Perrett

Funding

National Health and Medical Research Council Career Award

GSK

Research Group

Vaccine and Immunisation group research



Faculty Research Themes

Infection and Immunology, Child Health

School Research Themes

Disparities, disadvantage and effective health care



Key Contact

For further information about this research, please contact the research group leader.

Unit / Centre

Vaccine and Immunisation group research